Guest guest Posted January 9, 2006 Report Share Posted January 9, 2006 Norman, have you considered calling Dr. Bernard Bihari? Do you know who he is? (212-929-4196) Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 9, 2006 Report Share Posted January 9, 2006 > Norman, have you considered calling Dr. Bernard Bihari? Do you know who he > is? (212-929-4196) > > Thanks . I interviewed Bihari over the phone in Dec. 2004 and have talked with him several times since then. What I provided to the naltrexone network is potentially priceless, through my networking among researchers--so Bihari will speak with me when he has time. But he doesn't know anything about EDS, and none of the activists in the network have helped me to gather volunteers for the fibro and EDS case studies I designed with the input and verbal support of the NIH researcher in charge of the large current 5 yr connective tissue diagnostic study--who said she'd apply to do a pilot trial with LDN for EDS III if I could supply her with the evidence of successful case studies. Everybody is overloaded with work--it's the American way of " life. " So our priorities are what determines what gets done and what doesn't. And fibro is not a high priority among the network ingroup of LDN, to which I also belong. Nor is fibro a high priority with Dr. Sacerdote in Milan, to whom I have direct email & phone access. That's why fibro research needs to become a priority for a few people somewhere (a nurse who uses LDN for her fibro promised to shepherd the case studies in Atlanta, but she no longer keeps in contact with me, nor did she provide me with her pain specialist's contact info so I could work with him). I could even use a few allies in the EDS community. Norman Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.